The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
 
Yago Nieto
No Relationships to Disclose
 
Shi-Ming Tu
No Relationships to Disclose
 
Matthew T. Campbell
No Relationships to Disclose
 
Roland Bassett
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
John Francis Ward
No Relationships to Disclose
 
Wayne Lewis Hofstetter
No Relationships to Disclose
 
Roy B. Jones
Travel, Accommodations, Expenses - Velos
 
Borje Andersson
No Relationships to Disclose
 
Alison M Gulbis
No Relationships to Disclose
 
Celina Ledesma
No Relationships to Disclose
 
Melissa Timmons
No Relationships to Disclose
 
Michelle Trapp
No Relationships to Disclose
 
Richard E. Champlin
No Relationships to Disclose
 
Lance C. Pagliaro
Travel, Accommodations, Expenses - Roche